BRAIN-Engineered-Cas (BEC) Considered a Patentable Technology

11 January 2022, Zwingenberg (Germany) - BRAIN Biotech AG received an international search report and a written opinion from the European Patent Office (EPO) as international searching authority (ISA). The favorable written opinion states that the BRAIN-Engineered-Cas (BEC) nucleases for which patent protection is sought under the Patent Corporation Treaty (PCT) with an earliest priority date of around 18 months ago are novel, are – with regard to the BEC nuclease sequences – inventive, are industrially applicable and are also not otherwise excluded from patent protection. Hence, the respective sequences of the BEC nucleases are considered patentable by the EPO.